NM_000535.7(PMS2):c.326A>G (p.Glu109Gly) AND Hereditary cancer-predisposing syndrome

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: May 29, 2024
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV002442923.3

Allele description [Variation Report for NM_000535.7(PMS2):c.326A>G (p.Glu109Gly)]

NM_000535.7(PMS2):c.326A>G (p.Glu109Gly)

Gene:

PMS2:PMS1 homolog 2, mismatch repair system component [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

7p22.1

Genomic location:

Preferred name:

NM_000535.7(PMS2):c.326A>G (p.Glu109Gly)

HGVS:

NC_000007.14:g.6003717T>C
NG_008466.1:g.10390A>G
NM_000535.7:c.326A>GMANE SELECT
NM_001322003.2:c.-80A>G
NM_001322004.2:c.-80A>G
NM_001322005.2:c.-80A>G
NM_001322006.2:c.326A>G
NM_001322007.2:c.35+255A>G
NM_001322008.2:c.35+255A>G
NM_001322009.2:c.-80A>G
NM_001322010.2:c.-80A>G
NM_001322011.2:c.-559A>G
NM_001322012.2:c.-559A>G
NM_001322013.2:c.-80A>G
NM_001322014.2:c.326A>G
NM_001322015.2:c.-159A>G
NP_000526.2:p.Glu109Gly
NP_001308935.1:p.Glu109Gly
NP_001308943.1:p.Glu109Gly
LRG_161t1:c.326A>G
LRG_161:g.10390A>G
NC_000007.13:g.6043348T>C
NM_000535.5:c.326A>G
NR_136154.1:n.413A>G

Protein change:

E109G

Links:

dbSNP: rs1785367984

NCBI 1000 Genomes Browser:

rs1785367984

Molecular consequence:

NM_001322003.2:c.-80A>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001322004.2:c.-80A>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001322005.2:c.-80A>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001322009.2:c.-80A>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001322010.2:c.-80A>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001322011.2:c.-559A>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001322012.2:c.-559A>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001322013.2:c.-80A>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001322015.2:c.-159A>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001322007.2:c.35+255A>G - intron variant - [Sequence Ontology: SO:0001627]
NM_001322008.2:c.35+255A>G - intron variant - [Sequence Ontology: SO:0001627]
NM_000535.7:c.326A>G - missense variant - [Sequence Ontology: SO:0001583]
NM_001322006.2:c.326A>G - missense variant - [Sequence Ontology: SO:0001583]
NM_001322014.2:c.326A>G - missense variant - [Sequence Ontology: SO:0001583]
NR_136154.1:n.413A>G - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Name:: Hereditary cancer-predisposing syndrome
Synonyms:: Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:: MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Clear Turn Off Turn On

trnad-guc [Leucoraja erinaceus]
trnad-guc [Leucoraja erinaceus]
Gene ID:129716539

Gene
trnaf-gaa [Leucoraja erinaceus]
trnaf-gaa [Leucoraja erinaceus]
Gene ID:129716533

Gene
BioAssays, activity concentration at/below 1 uM for PubChem Compo... (12)
BioAssays, activity concentration at/below 1 uM for PubChem Compound (Select 117606729)
Search

PubChem BioAssay
BioProject Links for BioSample (Select 43929723) (0)
BioProject
Chain A, Natrinema pilin, Orf10
Chain A, Natrinema pilin, Orf10
gi|2563387099|pdb|8GI2|A

Protein

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV002612399	Ambry Genetics	criteria provided, single submitter (Ambry Variant Classification Scheme 2023)	Uncertain significance (May 29, 2024)	germline	clinical testing	Citation Link

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV002612399

Ambry Genetics

criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)

Uncertain significance
(May 29, 2024)

germline

clinical testing

Citation Link

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Details of each submission

From Ambry Genetics, SCV002612399.3

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	not provided

Description

The p.E109G variant (also known as c.326A>G), located in coding exon 4 of the PMS2 gene, results from an A to G substitution at nucleotide position 326. The glutamic acid at codon 109 is replaced by glycine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Sep 29, 2024

ClinVar

Relating variation to medicine